Enliven Therapeutics (ELVN) Other Non-Current Assets (2019 - 2026)

Enliven Therapeutics has disclosed Other Non-Current Assets across 8 years of filings, most recently posting $1.2 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $1.2 million, down 83.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (down 83.49% YoY), and the FY2025 annual result was $656000.0, down 90.86% from the prior year.
• Other Non-Current Assets came in at $1.2 million for Q1 2026 at Enliven Therapeutics, up from $656000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $7.6 million in Q2 2024 to a low of $54000.0 in Q1 2023.
• The 5-year median for Other Non-Current Assets is $4.1 million (2023), against an average of $3.6 million.
• Across the five-year window, Other Non-Current Assets soared 13903.7% in 2024 and slumped 90.86% in 2025, its largest moves.
• Enliven Therapeutics' Other Non-Current Assets stood at $175000.0 in 2022, then surged by 2237.71% to $4.1 million in 2023, then jumped by 75.38% to $7.2 million in 2024, then plunged by 90.86% to $656000.0 in 2025, then jumped by 81.1% to $1.2 million in 2026.
• The last three Other Non-Current Assets figures came in at $1.2 million (Q1 2026), $656000.0 (Q4 2025), and $7.1 million (Q3 2025), per Business Quant data.